Sanofi in Talks to Sell 50% Stake in Consumer Health Unit Opella for $17 Billion

Oct 12, 2024 13:08 CST Updated 13:08

Clayton, Dubilier & Rice

Global Investment Institution

Sanofi

Pharmaceutical R&D Developer

On October 11, according to the report of Cailian Press,Sanofi has negotiated with the U.S. private equity firm Clayton, Dubilier & Rice to sell its consumer health business.

Sanofi also confirmed on Friday,Has entered into negotiations with CD&R regarding the sale of a 50% controlling stake in its consumer health business, Opella.。

There are reports that the company's bid for this enterprise, which has 11,000 employees, is €15.5 billion (approximately $17 billion). According to the Financial Times,Sanofi ultimately plans to sell its remaining stake in the company over the next few years.

In the past few years, large MNC pharmaceutical companies have been divesting their consumer health businesses.

Johnson & Johnson split its consumer health division into Kenvue in August 2023, and the division is now valued at over $40 billion. The company manages well-known brands such as Tylenol, Listerine mouthwash, and Aveeno skin lotions.

End

Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly indicated. This official account welcomes sharing in friend circles or large groups.Reproduction in any form by media or institutions without authorization is prohibited.。

Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）

Business Cooperation

Call for Papers

Click to learn more

Previous Review

1	August \| Up to 22 pharmaceutical companies lay off employees
2	China's First Quadrivalent HPV Vaccine Developed Domestically Proposed for Priority Review
3	$3.7 Billion! The Largest Biomedical Financing of the Year is Born